Document is current
Any future updates will be listed below
-
Authors
González-Domínguez, Irene https://orcid.org/0000-0002-7920-5505
Puente-Massaguer, Eduard https://orcid.org/0000-0002-2816-7051
Abdeljawad, Adam https://orcid.org/0009-0006-2024-109X
Lai, Tsoi Ying
Liu, Yonghong
Loganathan, Madhumathi https://orcid.org/0000-0002-3751-8036
Francis, Benjamin
Lemus, Nicholas
Dolange, Victoria
Boza, Marta
Slamanig, Stefan https://orcid.org/0000-0003-3694-6597
Martínez-Guevara, Jose Luis
Krammer, Florian https://orcid.org/0000-0003-4121-776X
Palese, Peter https://orcid.org/0000-0002-0337-5823
Sun, Weina https://orcid.org/0000-0002-2435-5047
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (CIVICs, 75N93019C00051)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (CEIRR,75N93021C00014)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (P01 AI097092-07)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01 AI145870-03)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (CIVICs, 75N93019C00051)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (CEIRR,75N93021C00014)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (CIVICs, 75N93019C00051)
- License Information
-
More Information
Article History
Received: 29 May 2024
Accepted: 30 October 2024
First Online: 17 November 2024
Competing interests
: The Icahn School of Medicine at Mount Sinai and Dynavax have filed a patent application in which P.P., W.S., I.G.D. and F.K. are listed as co-inventors. The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays, NDV-based SARS-CoV-2 vaccines, influenza virus vaccines and influenza virus therapeutics which list F.K. as co-inventor. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2 and another company, Castlevax, to develop SARS-CoV-2 vaccines. F.K., P.P. and W.S. are co-founder of Castlevax. F.K. has consulted for Merck, Curevac, Seqirus and Pfizer and is currently consulting for 3rd Rock Ventures, GSK, Gritstone and Avimex. The Krammer laboratory is also collaborating with Dynavax on influenza A virus vaccine development. All other authors declare no competing interests.
